ES2039209T5 - Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica. - Google Patents

Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.

Info

Publication number
ES2039209T5
ES2039209T5 ES87100811T ES87100811T ES2039209T5 ES 2039209 T5 ES2039209 T5 ES 2039209T5 ES 87100811 T ES87100811 T ES 87100811T ES 87100811 T ES87100811 T ES 87100811T ES 2039209 T5 ES2039209 T5 ES 2039209T5
Authority
ES
Spain
Prior art keywords
human
capacity
csf
hemopoyetic
restoration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87100811T
Other languages
English (en)
Other versions
ES2039209T3 (es
Inventor
Masahiko Tamura
Kunihiro Hattori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11745897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2039209(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ES2039209T3 publication Critical patent/ES2039209T3/es
Application granted granted Critical
Publication of ES2039209T5 publication Critical patent/ES2039209T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UN AGENTE FARMACEUTICO QUE TIENE UNA COLONIA DE GRANULOCITOS HUMANOS, QUE ESTIMULAN EL FACTOR (G-CSF HUMANO) COMO INGREDIENTE ACTIVO Y QUE ES EFICAZ PARA PROMOVER LA RECUPERACION DE LA CAPACIDAD HOMOPOYETICA DE PACIENTES CON TRASTORNOS HOMOPOYETICOS, QUE HAN RECIBIDO EL TRATAMIENTO DE TRANSPLANTE DE MEDULA DE HUESO. G-CSFS HUMANOS QUE SON ADECUADOS PARA UTILIZAR EN UN AGENTE FARMACEUTICO DE LA PRESENTE INVENCION INCLUYEN LOS OBTENIDOS POR SEPARACION A PARTIR DE LIQUIDO SOBRENADANTE DEL CULTIVO DE CELULAS PRODUCTORAS DE G-CSF HUMANO Y POLIPEPTIDOS O GLICOPROTEINAS QUE TIENEN ACTIVIDAD G-CSF, QUE SE OBTIENEN MEDIANTE TECNOLOGIA RECOMBINANTE DE DNA.
ES87100811T 1986-01-22 1987-01-21 Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica. Expired - Lifetime ES2039209T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1028086 1986-01-22

Publications (2)

Publication Number Publication Date
ES2039209T3 ES2039209T3 (es) 1993-09-16
ES2039209T5 true ES2039209T5 (es) 1996-07-16

Family

ID=11745897

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87100811T Expired - Lifetime ES2039209T5 (es) 1986-01-22 1987-01-21 Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.

Country Status (5)

Country Link
EP (1) EP0230980B2 (es)
AT (1) ATE65403T1 (es)
CA (1) CA1297004C (es)
DE (1) DE3771509D1 (es)
ES (1) ES2039209T5 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0565722A1 (en) * 1990-12-25 1993-10-20 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical preparation for pernasal administration
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1998006422A1 (fr) 1996-08-13 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Agents de proliferation des cellules souches hematopoietiques
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
JP5715622B2 (ja) 2009-06-14 2015-05-07 バイオカイン セラピューティックス リミテッド 血小板レベルを増大させるためのペプチド療法
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
DE102014001250C5 (de) 2014-02-03 2021-07-29 Carl Freudenberg Kg Fensterwischer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) * 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.

Also Published As

Publication number Publication date
ATE65403T1 (de) 1991-08-15
EP0230980A3 (en) 1988-07-27
EP0230980A2 (en) 1987-08-05
EP0230980B1 (en) 1991-07-24
ES2039209T3 (es) 1993-09-16
DE3771509D1 (de) 1991-08-29
CA1297004C (en) 1992-03-10
EP0230980B2 (en) 1996-03-20

Similar Documents

Publication Publication Date Title
ES2039209T5 (es) Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ES2043890T3 (es) Nuevo uso medico.
ATE358176T1 (de) Menschliche dnase
DE3683430D1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
DE3778585D1 (de) Herzschrittmacher zur stimulierung des menschlichen herzens.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
WO1989000582A3 (en) Human granulocyte-macrophage colony stimulating factor and muteins thereof
MY104124A (en) Therapeutic compounds.
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
Crockett et al. Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis
ATE79272T1 (de) Acth(1-24) enthaltende pharmazeutische zusammensetzungen zur therapie von schockzustaenden und von respiratorischen und herzkreislauf-insuffizienzen.
EP0158880A3 (en) Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
KR100908628B1 (ko) Ｇ-ｃｓｆ를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물
EP0331088A3 (en) Remedy for hematopoietic tissue diseases comprising human monocytic macrophage colony stimulating factor as active ingredient
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання